Amikacin Sulfate

FDA-approved product (injectable, injection), marketed as Amikacin Sulfate, Amikacin Sulfate In Sodium Chloride 0.9% In Plastic Container, Amikin and 2 more.

Registered studies: 50+
Lab records: 133
Pathogens at ≥40%: 4 of 4

Chemical structure

A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

Bacterial disease
Eye infection
Infection
Infectious meningitis
Lung disease
Peritonitis
Respiratory tract infectious disorder
Sepsis
Staphylococcus aureus infection
Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group: Other antibiotics for topical use; Other aminoglycosides; Antibiotics
FDA pharmacologic class: Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification: Classified as an existing antimicrobial.WHO ATC J01GB06; WHO ATC D06AX12; WHO ATC S01AA21; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Amikacin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured

MRSA65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
E. coli60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
K. pneumoniae84.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
M. tuberculosis88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

MRSA: measured active in 1 of 1 lab record
E. coli: measured active in 6 of 8 lab records
K. pneumoniae: measured active in 73 of 115 lab records
M. tuberculosis: measured active in 9 of 9 lab records

Open Amikacin Sulfate in ChEMBL Registered studies below

Show the 133 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amikacin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

Condition

Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
NCT02081963 · start 2014-03
Registered record
Registry ID
NCT02081963
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Amikacin; Normal saline
Study type
INTERVENTIONAL
Phase
Phase 4
Registry status
Completed
Start
2014-03
Completion
2016-12
Enrolment
178
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Cystic Fibrosis Bronchiectasis
InterventionAmikacin; Normal saline
PhasePhase 4
Registry statusCompleted
In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation
NCT02084043 · start 2014-03
Registered record
Registry ID
NCT02084043
Conditions
Respiratory Diseases; Lung Diseases; Cystic Fibrosis; COPD; Asthma
Interventions
Nebulization of Amikacin during NIV (RR: 15 cycles/minute); Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
2014-03
Completion
2015-06
Enrolment
3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRespiratory Diseases; Lung Diseases; Cystic Fibrosis; COPD +1 more
InterventionNebulization of Amikacin during NIV (RR: 15 cycles/minute); Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
PhaseNot applicable
Registry statusCompleted
Which Apparatus for Inhaled Pentamidine?
NCT02277808 · start 2013-12
Registered record
Registry ID
NCT02277808
Conditions
Healthy
Interventions
500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%); Respirgard II; Isoneb®
Study type
INTERVENTIONAL
Phase
Early phase 1
Registry status
Unknown
Start
2013-12
Completion
Not recorded
Enrolment
10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy
Intervention500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%); Respirgard II; Isoneb®
PhaseEarly phase 1
Registry statusUnknown
Pharmacokinetics of Nebulized Amikacin in Non Invasive Ventilated Healthy Volunteers.
NCT01901497 · start 2013-07
Registered record
Registry ID
NCT01901497
Conditions
Acute Respiratory Insufficiency; Chronic Respiratory Insufficiency; Bronchospasm and Obstruction
Interventions
Nebulizer
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
2013-07
Completion
2016-01
Enrolment
7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Respiratory Insufficiency; Chronic Respiratory Insufficiency; Bronchospasm and Obstruction
InterventionNebulizer
PhaseNot applicable
Registry statusCompleted
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
NCT01316276 · start 2012-10-05
Registered record
Registry ID
NCT01316276
Conditions
Cystic Fibrosis
Interventions
Liposomal amikacin for inhalation
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Completed
Start
2012-10-05
Completion
2015-07-16
Enrolment
206
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCystic Fibrosis
InterventionLiposomal amikacin for inhalation
PhasePhase 3
Registry statusCompleted
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT01659866 · start 2012-08
Registered record
Registry ID
NCT01659866
Conditions
Infection
Interventions
Ciprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem
Study type
INTERVENTIONAL
Phase
Phase 4
Registry status
Completed
Start
2012-08
Completion
2016-08
Enrolment
563
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection
InterventionCiprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone +9 more
PhasePhase 4
Registry statusCompleted
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
NCT01315236 · start 2012-04-19
Registered record
Registry ID
NCT01315236
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Liposomal amikacin for inhalation (LAI); placebo
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2012-04-19
Completion
2015-06-18
Enrolment
90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMycobacterium Infections, Nontuberculous
InterventionLiposomal amikacin for inhalation (LAI); placebo
PhasePhase 2
Registry statusCompleted
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
NCT01315678 · start 2012-02-29
Registered record
Registry ID
NCT01315678
Conditions
Pseudomonas Aeruginosa Infection
Interventions
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.; Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Completed
Start
2012-02-29
Completion
2013-09-18
Enrolment
302
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPseudomonas Aeruginosa Infection
InterventionLiposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.; Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
PhasePhase 3
Registry statusCompleted
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
NCT01431326 · start 2011-11
Registered record
Registry ID
NCT01431326
Conditions
Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; C
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Study type
OBSERVATIONAL
Phase
Not recorded
Registry status
Completed
Start
2011-11
Completion
2019-11
Enrolment
3,520
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdenovirus; Anesthesia; Anxiety; Anxiolysis +47 more
InterventionThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
PhaseNot recorded
Registry statusCompleted
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
NCT01570192 · start 2010-09
Registered record
Registry ID
NCT01570192
Conditions
Bacterial Pneumonia
Interventions
IV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h; Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.; tobramycin nebulization
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Terminated
Start
2010-09
Completion
2015-04
Enrolment
43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Pneumonia
InterventionIV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h +3 more
PhasePhase 2
Registry statusTerminated
Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic
NCT00950222 · start 2009-06
Registered record
Registry ID
NCT00950222
Conditions
Ventilator Associated Pneumonia
Interventions
Imipenem/Amikacin
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
2009-06
Completion
2012-01
Enrolment
70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVentilator Associated Pneumonia
InterventionImipenem/Amikacin
PhaseNot applicable
Registry statusCompleted
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
NCT00775138 · start 2008-06-24
Registered record
Registry ID
NCT00775138
Conditions
Bronchiectasis
Interventions
280 mg Arikayce™; Matching Placebo for Cohort 1; 560 mg Arikayce™; Matching Placebo for Cohort 2
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2008-06-24
Completion
2009-05-11
Enrolment
64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBronchiectasis
Intervention280 mg Arikayce™; Matching Placebo for Cohort 1; 560 mg Arikayce™; Matching Placebo for Cohort 2
PhasePhase 2
Registry statusCompleted
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
NCT00515034 · start 2007-10
Registered record
Registry ID
NCT00515034
Conditions
Pneumonia, Ventilator-Associated; Pneumonia, Bacterial; Pneumonia; Abdominal Abscess; Bacterial Infections
Interventions
Imipenem/cilastatin; Imipenem/cilastatin; Doripenem; Doripenem
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2007-10
Completion
2008-11
Enrolment
146
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Ventilator-Associated; Pneumonia, Bacterial; Pneumonia; Abdominal Abscess +1 more
InterventionImipenem/cilastatin; Imipenem/cilastatin; Doripenem; Doripenem
PhasePhase 2
Registry statusCompleted
Antiseptic Use and Dressing Application
NCT00389558 · start 2006-09
Registered record
Registry ID
NCT00389558
Conditions
Skin Colonization; Catheterization; Bacterial Infection
Interventions
disinfection efficacy using Biseptine; disinfection efficacy using Amukin
Study type
INTERVENTIONAL
Phase
Phase 4
Registry status
Completed
Start
2006-09
Completion
2008-10
Enrolment
453
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Colonization; Catheterization; Bacterial Infection
Interventiondisinfection efficacy using Biseptine; disinfection efficacy using Amukin
PhasePhase 4
Registry statusCompleted
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
NCT00786305 · start 2004-10
Registered record
Registry ID
NCT00786305
Conditions
Pneumonia
Interventions
ceftazidime and amikacin; ceftazidime and amikacin
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2004-10
Completion
2008-11
Enrolment
40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia
Interventionceftazidime and amikacin; ceftazidime and amikacin
PhasePhase 2
Registry statusCompleted

Existing / approved use

Repurposing investigation

AI-predicted activity

Evidence

Clinical and experimental

Docking

Other medicines to investigate

Registered studies